Company Filing History:
Years Active: 2013-2016
Title: **The Innovative Journey of Patricia Aus Dem Siepen**
Introduction
Patricia Aus Dem Siepen is a notable inventor based in Feldafing, Germany. With a passion for biotechnological advancements, she has made significant contributions to the field of medical research. Her innovative work primarily revolves around the development of FGFR4 antibodies, which hold promise for various therapeutic applications.
Latest Patents
Patricia holds two patents that focus on FGFR4 antibodies. These innovative patents encompass not only the antibodies themselves but also their fragments and derivatives, along with the polynucleotides that encode them. The technology also includes expression vectors and host cells that comprise these polynucleotides. The inventions refer to pharmaceutical compositions made with FGFR4 antibodies, which are aimed at the treatment, prevention, or diagnosis of disorders associated with FGFR4 expression. This work has the potential to impact many lives by advancing therapeutic options in the medical field.
Career Highlights
Patricia is currently employed at U3 Pharma GmbH, where she continues her research and development efforts. Her expertise in the field has led to significant advancements in biotechnologies, particularly in the realm of antibody therapies. Over the course of her career, she has demonstrated a commitment to utilizing her innovative skills to tackle important health challenges.
Collaborations
Patricia collaborates with esteemed colleagues such as Johannes Bange and Jens Niewoehner. Together, they contribute to the innovative environment at U3 Pharma GmbH, fostering research that aims to improve therapeutic outcomes for patients with disorders related to FGFR4 expression.
Conclusion
Patricia Aus Dem Siepen's contributions to the field of biotechnology, particularly through her patents on FGFR4 antibodies, exemplify the important role of inventors in advancing medical science. Her ongoing work at U3 Pharma GmbH and collaboration with talented peers highlights the collective effort required to innovate and improve healthcare solutions.